title: Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies.
abstract: OBJECTIVE
  To characterize the alpha 1-adrenoceptor subtypes of the human benignly enlarged prostate using functional and binding studies.
  
  
  METHODS
  Strips of prostatic tissue taken from nine patients with benign prostatic hypertrophy who were undergoing open prostatectomy were used in the study.
  
  
  RESULTS
  The strips isolated from five prostates produced a large contraction in response to noradrenaline and phenylephrine but not to clonidine. The contractile response induced by noradrenaline was competitively antagonized by representative alpha 1-adrenoceptor antagonists (prazosin, WB4101, 5-methylurapidil and HV723), the dissociation constants (pKB) being < 8.5. Pre-treatment with chloroethylclonidine was without effect on the contractile response to noradrenaline. In saturation experiments with five prostates, [3H]-prazosin bound to the prostate membranes with two distinct affinities (pKD = 9.95 +/- 0.07 and 8.71 +/- 0.04, Bmax = 151 +/- 8 and 138 +/- 3 fmol/mg protein, respectively). Unlabelled prazosin and WB4101 biphasically displaced the binding of 200 pM [3H]-prazosin; the resulting high and low pKI values for each of the antagonists were consistent with the two pKD values obtained for [3H]-prazosin in the saturation experiments. 5-Methylurapidil and HV723 displaced the [3H]-prazosin binding monophasically with an affinity (pKI) close to 8.5.
  
  
  CONCLUSIONS
  These results suggest the presence of at least two distinct alpha 1-adrenoceptor subtypes (presumably an alpha 1C subtype with a high affinity for prazosin and WB4101, and a putative alpha 1L subtype with a low affinity for the antagonists) in the human prostate, in which the latter subtype may be predominantly involved in the contractile response to noradrenaline.
authors.affiliation: Department of Pharmacology, Fukui Medical School, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Muramatsu
authors.forename: M
authors.initials: M
authors.lastname: Oshita
authors.forename: T
authors.initials: T
authors.lastname: Ohmura
authors.forename: S
authors.initials: S
authors.lastname: Kigoshi
authors.forename: H
authors.initials: H
authors.lastname: Akino
authors.forename: M
authors.initials: M
authors.lastname: Gobara
authors.forename: K
authors.initials: K
authors.lastname: Okada
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000378:metabolism*; D001667:Binding, Competitive; D003000:Clonidine / Q000378:metabolism; D004146:Dioxanes / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009132:Muscles / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010656:Phenylephrine / Q000378:metabolism; D011224:Prazosin / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*
chemical_list: D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D018340:Receptors, Adrenergic, alpha-1; D010656:Phenylephrine; C010654:(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; D003000:Clonidine; D009638:Norepinephrine; D011224:Prazosin